Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115847529> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3115847529 abstract "Abstract Background: Since the first detection of a bunch of COVID-19 in late 2019, it become a global concern due to its transmissibility and ability to progress patients in severe respiratory failure and acute respiratory distress syndrome, which need intensive care unit support for a long time. We observed the repurposing use of remdesivir and favipiravir whether considered as a therapeutic option or not through survival rate and changes in biomarker during 10-day treatment stay in ICU. Materials and method: The retrospective observational study in a tertiary care hospital dedicated to COVID-19 at Dhaka, Bangladesh was done at the peak of COVID-19 pandemic in Bangladesh. The mortality rate, length of ICU stays and eight prognostic biomarkers of patients treated with remdesivir and favipiravir was observed as one of the first ever reported experience in Bangladesh. Results: Among the critically ill patients in ICU, 26 (44.8%) died and 32 (55.2%) were cured during the study period and highest mean duration of stay in ICU was observed (14.33 days and 18.13 days) in FPV-treated patients. Mean of means for all biomarkers CRP (26.0) and d-Dimer (2.64) was recorded higher in favipiravir treated patients in death cases, but NLR, d-NLR, platelet, PLR was much higher in remdesivir treated patient of both death and improved cases. Though overall outcome variables between death and improved cases were not statistically significant (p<0.39) Conclusion: The severity of disease progression in critically ill COVID-19 patients in ICU depends on comorbidities and hyper responsive inflammatory or immunological biomarkers to predict. Though the emergency use authorization and repurposing use of different antivirals are still on trial, but remdesivir and favipiravir revealed not much hope in improving prognostic biomarkers, survival rate and disease progression at the initial peak of pandemic in Bangladesh." @default.
- W3115847529 created "2021-01-05" @default.
- W3115847529 creator A5010150920 @default.
- W3115847529 creator A5030587581 @default.
- W3115847529 creator A5050443482 @default.
- W3115847529 creator A5051441318 @default.
- W3115847529 creator A5055960611 @default.
- W3115847529 date "2020-12-08" @default.
- W3115847529 modified "2023-09-27" @default.
- W3115847529 title "Survival and Biomarkers of COVID-19 Patients Treated with Remdesivir and Favipiravir in ICU: A Single Center Experience in Bangladesh" @default.
- W3115847529 doi "https://doi.org/10.21203/rs.3.rs-123710/v1" @default.
- W3115847529 hasPublicationYear "2020" @default.
- W3115847529 type Work @default.
- W3115847529 sameAs 3115847529 @default.
- W3115847529 citedByCount "0" @default.
- W3115847529 crossrefType "posted-content" @default.
- W3115847529 hasAuthorship W3115847529A5010150920 @default.
- W3115847529 hasAuthorship W3115847529A5030587581 @default.
- W3115847529 hasAuthorship W3115847529A5050443482 @default.
- W3115847529 hasAuthorship W3115847529A5051441318 @default.
- W3115847529 hasAuthorship W3115847529A5055960611 @default.
- W3115847529 hasBestOaLocation W31158475291 @default.
- W3115847529 hasConcept C126322002 @default.
- W3115847529 hasConcept C167135981 @default.
- W3115847529 hasConcept C177713679 @default.
- W3115847529 hasConcept C179755657 @default.
- W3115847529 hasConcept C194828623 @default.
- W3115847529 hasConcept C23131810 @default.
- W3115847529 hasConcept C2776348555 @default.
- W3115847529 hasConcept C2776376669 @default.
- W3115847529 hasConcept C2777714996 @default.
- W3115847529 hasConcept C2779134260 @default.
- W3115847529 hasConcept C2779772310 @default.
- W3115847529 hasConcept C30036603 @default.
- W3115847529 hasConcept C3008058167 @default.
- W3115847529 hasConcept C524204448 @default.
- W3115847529 hasConcept C71924100 @default.
- W3115847529 hasConceptScore W3115847529C126322002 @default.
- W3115847529 hasConceptScore W3115847529C167135981 @default.
- W3115847529 hasConceptScore W3115847529C177713679 @default.
- W3115847529 hasConceptScore W3115847529C179755657 @default.
- W3115847529 hasConceptScore W3115847529C194828623 @default.
- W3115847529 hasConceptScore W3115847529C23131810 @default.
- W3115847529 hasConceptScore W3115847529C2776348555 @default.
- W3115847529 hasConceptScore W3115847529C2776376669 @default.
- W3115847529 hasConceptScore W3115847529C2777714996 @default.
- W3115847529 hasConceptScore W3115847529C2779134260 @default.
- W3115847529 hasConceptScore W3115847529C2779772310 @default.
- W3115847529 hasConceptScore W3115847529C30036603 @default.
- W3115847529 hasConceptScore W3115847529C3008058167 @default.
- W3115847529 hasConceptScore W3115847529C524204448 @default.
- W3115847529 hasConceptScore W3115847529C71924100 @default.
- W3115847529 hasLocation W31158475291 @default.
- W3115847529 hasLocation W31158475292 @default.
- W3115847529 hasOpenAccess W3115847529 @default.
- W3115847529 hasPrimaryLocation W31158475291 @default.
- W3115847529 hasRelatedWork W1979561912 @default.
- W3115847529 hasRelatedWork W1999437375 @default.
- W3115847529 hasRelatedWork W2048391620 @default.
- W3115847529 hasRelatedWork W2050506665 @default.
- W3115847529 hasRelatedWork W2281416424 @default.
- W3115847529 hasRelatedWork W2610641036 @default.
- W3115847529 hasRelatedWork W2795151333 @default.
- W3115847529 hasRelatedWork W2810184270 @default.
- W3115847529 hasRelatedWork W2854318780 @default.
- W3115847529 hasRelatedWork W4296361120 @default.
- W3115847529 isParatext "false" @default.
- W3115847529 isRetracted "false" @default.
- W3115847529 magId "3115847529" @default.
- W3115847529 workType "article" @default.